InvestorsHub Logo
Followers 31
Posts 779
Boards Moderated 0
Alias Born 08/03/2020

Re: justdafactss post# 140869

Saturday, 01/16/2021 1:43:53 PM

Saturday, January 16, 2021 1:43:53 PM

Post# of 233271
Thanks for posting that so that we can adjust our expectations. I am very, very anxious to see results.

I believe investors, the media, the FDA and a few sick patients are as well.

I hope that Cytodyn and Amarex substantially quicker at releasing results than was Norvartis.


Study Type : Interventional (Clinical Trial)
Actual Enrollment : 432 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)
Actual Study Start Date : May 2, 2020
Actual Primary Completion Date : October 17, 2020
Actual Study Completion Date : October 17, 2020



https://clinicaltrials.gov/ct2/show/NCT04362137?term=NCT04362137&draw=2&rank=1

I retrieved my fancy calculator and made a disheartening discovery.

With the trial ending October 17 and the results not released until December 14, 61 full days passed before these disappointing results were released.

CD12 completed January 13 (28 days after full enrollment date of December 16

The CD12 trial completed enrollment with 394 patients on December 16


https://www.cytodyn.com/investors/news-events/press-releases/detail/493/fda-provides-guidance-for-adding-an-open-label-extension-to

Certainly you should not be worried for another (61-3) 58 days.

Check back in March!!

Whataboutdat?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News